LONDON, Sept. 29, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, provided the following details regarding its upcoming Research and Development Day scheduled for 14 October, 2014:
Location: New York City
Date: 14 October, 2014
Time: Registration begins at 9:30 a.m. ET, program from 10:00 a.m. ET – 1:00 p.m. ET
Agenda: The program will provide an update on GW's product pipeline and is expected to include presentations on the science and application of cannabinoids, updated data from the Epidiolex® epilepsy expanded access program, and a review of current pipeline programs including initial data from GW's ulcerative colitis Phase 2a clinical trial.
In addition to GW presenters, guest speakers will include:
Dr. Vincenzo Di Marzo, Director of the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Naples, Italy and one of the world's leading cannabinoid scientists
Dr. Elizabeth Thiele, Director of the Pediatric Epilepsy Program at Massachusetts General Hospital and Harvard Professor of Neurology
Dr. Orrin Devinsky, Director the NYU Comprehensive Epilepsy Center and Professor of Neurology, Neurosurgery and Psychiatry at the NYU School of Medicine
Attendees are requested to RSVP to Stephen Schultz, Vice President of Investor Relations. A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 26 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex® in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
CONTACT: Enquiries: GW Pharmaceuticals plc Justin Gover, Chief Executive Officer Stephen Schultz, VP Investor Relations (U.S.) (Today) +44 20 3727 1000 (Thereafter) + 44 1980 557000 917 280 2424 / 401 500 6570 FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway / John Dineen (UK) Robert Stanislaro (U.S.) + 44 20 3727 1000 212 850 5657 Trout Group, LLC (U.S. investor relations) Todd James / Chad Rubin 646 378 2900Source:GW Pharmaceuticals plc